inspirator schreef op 22 augustus 2017 08:20:
Gaat Gliead met Galapagos ervandoor; dan koerswaarde Galapagos in een zucht 100 euro.
Gilead Sciences (GILD) has gained 13% during the past three months as investors have started to bet that the beaten-down biotech stock has finally found a bottom. But do you need to buy Gilead now?
ILLUSTRATION: PIXABAY
That seems to be the key debate around Gilead, say Jefferies analyst Michael Yee and team, who ask "whether there is urgency to buy it now." They explain:
...relative increasing interest as biotech has turned more favorable since June and relative growing sense GILD has seen the bottom. Key investor debate is whether there is urgency to have to buy it now vs it's still a little early and perhaps wait for 2018 with more HCV clarity after AbbVie (ABBV) launches/formulary access and mkt share is more clear, 2018 EPS is more clear, and closer to Phase III filgotinib and Phase III NASH data in 2019. We are clear if they did a large M&A deal likeVertex Pharmaceuticals (VRTX) (written about previously), stock would likely re-rate higher given completely changed story, but mgmt seems most likely to not want to do large M&A and wait for more string-of-pearls deals.